Skip to main content

Dr. Marshall P. Stagg II, MD

Hematology & Oncology (Hematology & Oncology Physician)

8585 Picardy Ave, Suite 312
Baton Rouge, LA 70809

Who else practices at this address →

East Baton Rouge Parish includes primary care (46% of residents) shortage areas. About shortage areas

Call (225) 341-8311

  • Medicare participating

At a glance

Years since graduation
40
In the NPI registry since
2005
Medicare patients seen, 2024
86

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1986Medical school: Louisiana State University School of Medicine in New Orleans
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    LA license 019154

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
86
Services billed
522
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes16158
Established patient office or other outpatient visit, 40-54 minutes11428
Established patient office or other outpatient visit, 20-29 minutes6852

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 38 companies reported 154 payments worth $6,615 in total to this clinician.

By type
Food and Beverage$3,973
Consulting Fee$1,500
Long term medical supply or device loan$1,000
Education$142

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 17, 2025AbbVie Inc.
Nov 17, 2025
Consulting Fee
EPKINLY · ONCOLOGY
$1,500
Jun 2, 2025Janssen Biotech, Inc.
Jun 2, 2025
Education
DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind
$99.00
Oct 23, 2025Novartis Pharmaceuticals Corporation
Oct 23, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Nov 26, 2025Novartis Pharmaceuticals Corporation
Nov 26, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Dec 30, 2025Novartis Pharmaceuticals Corporation
Dec 30, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Sep 19, 2025Novartis Pharmaceuticals Corporation
Sep 19, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jan 23, 2025Novartis Pharmaceuticals Corporation
Jan 23, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Feb 21, 2025Novartis Pharmaceuticals Corporation
Feb 21, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Mar 26, 2025Novartis Pharmaceuticals Corporation
Mar 26, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
May 15, 2025Novartis Pharmaceuticals Corporation
May 15, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
All 15 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 30, 2025Novartis Pharmaceuticals Corporation
Dec 30, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Nov 26, 2025Novartis Pharmaceuticals Corporation
Nov 26, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Nov 19, 2025AstraZeneca Pharmaceuticals LP
Nov 19, 2025
Education
ENHERTU · Oncology · in-kind
Company’s descriptionJournal Article
$43.25
Nov 17, 2025AbbVie Inc.
Nov 17, 2025
Consulting Fee
EPKINLY · ONCOLOGY
$1,500
Oct 23, 2025Novartis Pharmaceuticals Corporation
Oct 23, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Sep 19, 2025Novartis Pharmaceuticals Corporation
Sep 19, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Aug 21, 2025Novartis Pharmaceuticals Corporation
Aug 21, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jul 25, 2025Novartis Pharmaceuticals Corporation
Jul 25, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jun 12, 2025Novartis Pharmaceuticals Corporation
Jun 12, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jun 2, 2025Janssen Biotech, Inc.
Jun 2, 2025
Education
DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind
$99.00
May 15, 2025Novartis Pharmaceuticals Corporation
May 15, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Apr 24, 2025Novartis Pharmaceuticals Corporation
Apr 24, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Mar 26, 2025Novartis Pharmaceuticals Corporation
Mar 26, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Feb 21, 2025Novartis Pharmaceuticals Corporation
Feb 21, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jan 23, 2025Novartis Pharmaceuticals Corporation
Jan 23, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Louisiana →

Industry-funded research

Named as a principal investigator on 22 industry-funded studies in 2025, from 12 companies. The companies reported $490,331 in research payments for these studies, mostly to the institutions running them.

  • An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Part…
    Merck Sharp & Dohme LLC
  • A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platin…
    Merck Sharp & Dohme LLC
  • A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refract…
    Celgene Corporation
  • A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (…
    Amgen Inc.
  • A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
    Novartis Pharmaceuticals Corporation
  • A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
    Karyopharm Therapeutics Inc.
  • A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvaluma…
    Amgen Inc.
  • An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers
    AstraZeneca UK Limited
  • A Noninterventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Advanced or Metastatic Malignancies
    Amgen Inc.
  • ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
    E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05949684

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Baton Rouge

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 7, 2022), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1841281573. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.